Vertex Pharmaceuticals And 2 Other Top Biotech Stocks To Own

Bond markets are loud again. Government borrowing costs sit near multi decade highs, which makes every dollar of future cash flow work harder to justify its value today. That kind of pressure can punish weaker companies, yet it also filters for drug developers with solid balance sheets and realistic valuations. This piece highlights three biotech stocks that clear that bar and may merit a closer look.

The three biotech stocks covered below are only a small sample, and the full screen surfaced 77 more listed drug developers with equally compelling stories that are not discussed here. To identify high conviction opportunities with similar balance sheet strength and valuation support, head straight into the Biotech Stocks screener.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals is the heavyweight in this biotech screener, with its cystic fibrosis portfolio already on the market and a broader rare disease pipeline that gives you a mix of current cash generation and potential future high reward shots on goal.

Vertex Pharmaceuticals develops specialty treatments for serious genetic conditions, anchored by its cystic fibrosis franchise that typifies the high reward biotech theme. The business generated about US$12.6b from pharmaceuticals and carries a market value near US$133.5b.

"While Vertex Pharmaceuticals is expanding JOURNAVX prescriptions and payer coverage, the decision to fund patient support programs until at least mid 2027 means the gross to net profile is not expected to normalize to roughly 50% for several more years."

How attractive Vertex Pharmaceuticals looks over the next few years may hinge on how one quietly building cost and pricing trade off ultimately resolves.

That trade off is exactly what the full narrative for Vertex Pharmaceuticals unpacks in detail. It shows where pricing pressure, pipeline momentum and capital allocation could be quietly decoupling.

Exelixis (EXEL)

Exelixis is a pure play oncology biotech, with CABOMETYX and COMETRIQ providing cancer drugs already on the market and a deep pipeline in the lab. This is the combination of attributes this screener is designed to highlight.

Exelixis generates about US$2.4b from discovering, developing and commercializing treatments for difficult to treat cancers, and carries a market value near US$14.5b.

"The recent introduction and uptake of CABOMETYX in neuroendocrine tumors, alongside its ongoing role in renal cell carcinoma, continues to support an expanding treated patient base in difficult to treat tumor types. This can underpin future revenue and earnings as the cabozantinib franchise moves toward its patent expiry window around 2030."

What investors may want to monitor closely is how a single shift in the timing and strength of the next oncology franchise could reshape the overall earnings profile.

That hinges on how you think the next oncology engine could reshape Exelixis, so read the full narrative for Exelixis to see where the risk reward really shifts.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals is a large biotech player for this screen because it already earns US$15.5b from discovering, developing and commercializing biologic medicines, while a market cap around US$74.9b reflects how seriously investors treat its mix of established drugs and high risk research programs.

Regeneron Pharmaceuticals gives you a very different flavour of biotech risk in this screen, with mature blockbuster biologics already generating meaningful cash and a broad next wave of science heavy programs that could either extend that strength or expose new pressure points.

"Although Dupixent currently anchors Regeneron Pharmaceuticals as a leading immunology franchise with large underpenetrated indications, management already flags that year over year growth is expected to moderate in the second half of 2026 as recent launches annualize and comparisons get tougher, which could slow the pace of revenue and earnings expansion just as investors extrapolate current growth rates."

What really matters next is how one emerging source of strain interacts with that slowing anchor to reshape both pricing power and earnings quality.

That turning point is exactly what the full narrative for Regeneron Pharmaceuticals maps out, revealing where slowing Dupixent growth could still mask fresh drivers for Regeneron Pharmaceuticals.

Seeking Fresh Alternatives Beyond Biotech?

Markets move fast and the best breakout ideas often fly under the radar for now. Scan fresh momentum while it matters, before the crowd catches on, and get in early.

• Target resilient compounding by reviewing a curated 32 resilient stocks with low risk scores that aims to hold up when volatility bites and weaker balance sheets start dropping.
• Ride potential infrastructure momentum through a hand picked 39 power grid technology and infrastructure stocks focused on businesses tied to grid upgrades, electrification, and long term capital cycles.
• Track metals that back real assets by scanning the selectively filtered 36 elite gold producer stocks before renewed interest pulls valuations higher and opportunity feels crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com